AOD-9604 human studies: what the actual trial data shows

Last updated 2026-07-25

What is AOD-9604 and why was it studied for fat loss?

AOD-9604 is a fragment of the human growth hormone molecule, built from amino acids 176-191 of the C-terminal region. The idea behind it goes back to older growth hormone research: GH has two main effects, it builds tissue (the growth-promoting part) and it releases fat from cells (the lipolytic part). Researchers wanted the fat-burning piece without the growth piece, since the growth side of GH carries risks like joint swelling, insulin resistance, and organ growth. The C-terminal fragment was the candidate that looked like it kept some fat-metabolizing activity while dropping most of the growth-hormone-receptor binding that drives cell growth. That's the whole pitch: a piece of GH that supposedly still tells fat cells to release stored fat, without acting like full GH everywhere else in the body. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604 specifically as a metabolic fragment of GH under investigation for obesity, distinguishing it from GH's growth-promoting activity ^[1]. That's the rationale in one sentence, and it's a real, coherent piece of biochemistry. Whether it translated into meaningful fat loss in actual humans is a separate question, and that's where the story gets less exciting. If you want the full background on what AOD-9604 is and how it's positioned today, the AOD-9604 peptide overview covers the mechanism in more depth.

Did AOD-9604 pass human clinical trials for obesity?

AOD-9604 went through human trials, including Phase IIb testing for obesity in the mid-2000s, run by the Australian company Metabolic Pharmaceuticals. It did not fail on safety. It failed to show a weight-loss effect that separated convincingly from placebo at a size and consistency that would satisfy a regulator. This is the central fact anyone researching AOD-9604 needs to sit with before spending money on it. A 2006 review of obesity drugs in clinical development, published in Current Opinion in Investigational Drugs, covers AOD-9604 within the pipeline of obesity compounds being tested at the time ^[2]. The peptide reached a stage of human testing that most compounds never reach, which says something about the initial promise. But reaching Phase IIb and clearing that bar are different things, and AOD-9604 never advanced to Phase III or to an FDA or TGA approval for obesity. There's no FDA-approved product containing AOD-9604 for any indication, and it does not appear in the Drugs@FDA database of approved drug products ^[3]. That absence is not a paperwork technicality. It reflects the fact that no sponsor has produced a trial package strong enough to support an approval. A useful comparison: tesamorelin, a GH-releasing hormone analog, went through full randomized controlled trials and got FDA approval in 2010 for HIV-associated lipodystrophy, with published data showing measurable visceral fat reduction. If you want to see how a peptide with an actual approval and reproducible trial data compares to AOD-9604 on paper, the AOD-9604 vs tesamorelin comparison lays out the difference plainly.

How strong is the placebo-controlled evidence for AOD-9604 fat loss?

Weak, and that's the honest, unglamorous summary. The core problem isn't that AOD-9604 trials showed zero effect. It's that whatever effect showed up wasn't reliably distinguishable from what a sugar pill and a calorie deficit produce on their own. When a weight-loss compound works, you expect the treatment arm to separate from placebo by a clinically meaningful margin, consistently, across multiple trial sites and doses. That's the standard the FDA and other regulators use to decide an obesity drug earns approval. AOD-9604's human obesity program didn't clear that bar, which is exactly why it never became an approved obesity drug and instead sits in an odd space between failed pharmaceutical candidate and freely available research chemical. The 2004 investigational drugs review frames AOD-9604 within the context of its metabolic fragment research rather than reporting a finished, positive efficacy verdict ^[1]. That framing matters. It tells you the compound was still being characterized and tested, not confirmed. Nobody should read "went through Phase IIb trials" as equivalent to "proved effective." Those are very different claims, and the gap between them is where a lot of marketing language for AOD-9604 tries to live.

Is AOD-9604 banned by WADA or detectable in doping tests?

No, AOD-9604 is not currently on the WADA prohibited list, and a 2013 study in Drug Testing and Analysis found it does not trigger the WADA hGH isoform immunoassay, the standard test used to catch growth hormone doping ^[4]. That's a specific, narrow finding worth being precise about: it means the standard hGH test won't flag AOD-9604 use, not that AOD-9604 is guaranteed permanently invisible to every possible detection method. Anti-doping science has moved toward more sensitive mass spectrometry methods for exactly this reason, to catch peptides that dodge older immunoassays. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviews analytical approaches for detecting emerging therapeutics and non-approved drugs in doping controls, covering the broader push to catch small peptides that older tests miss ^[5]. A companion 2014 review in Expert Review of Proteomics covers detection strategies specifically for peptidic drugs, drug candidates, and their analogs in sports doping ^[6]. A 2016 study in the Journal of Separation Science describes a method for screening peptides under 2 kilodaltons, using direct urine injection with liquid chromatography and ion mobility mass spectrometry, expanding what anti-doping labs can catch in that small-molecule-weight range where AOD-9604 sits ^[7]. AOD-9604 is roughly 1.8 kDa, squarely in the size range these newer methods target. If you're an athlete subject to testing, "not currently flagged by the standard hGH test" is not the same as "cleared for use." Check your governing body's current prohibited list before assuming anything about a peptide's status is fixed.

Does AOD-9604 have any legitimate approved medical use?

No. AOD-9604 has no FDA-approved indication, and it does not appear on either the FDA's 503A bulk drug substances list ^[8] or the 503B bulk drug substances list ^[9], the two lists that determine what compounding pharmacies can legally use to make patient-specific or office-stock preparations under federal law. Under 21 U.S.C. 353a, compounding pharmacies can prepare drugs from bulk substances for individual patients under specific conditions, but only using substances that meet the statute's requirements, generally meaning substances with an active ingredient in an FDA-approved drug or ones added to the 503A bulks list after FDA and expert panel review ^[10]. AOD-9604 hasn't cleared that review. The FDA's own page on bulk drug substances used in compounding under Section 503A explains the nomination and review process compounders must go through before a substance can be legally used this way ^[11], and AOD-9604 does not currently appear on the FDA's list of substances nominated and evaluated for that use ^[12]. Practically, this means AOD-9604 sold or compounded for human use in the US sits outside the framework the FDA built for legitimate compounding. It's typically sold and marketed as a research chemical, not a medical product, and any framing of it as a doctor-prescribed weight-loss treatment should be treated with real skepticism given this regulatory gap.

What do the newer 2026 peptide reviews say about AOD-9604?

Two 2026 reviews put AOD-9604 in the broader context of peptide therapeutics rather than treating it as a settled, well-supported compound. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics, including applications, challenges, and future directions for peptide-based treatments in that field ^[13]. A second 2026 review in Sports Medicine covers the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[14]. Both papers treat AOD-9604 as part of a larger, fast-moving category of peptides being used off-label or informally, well ahead of the regulatory and evidence base catching up. That's a fair description of where things stand in 2026: interest in peptide therapeutics keeps growing, research chemical suppliers keep selling AOD-9604 and similar compounds, and the underlying human efficacy data for fat loss specifically hasn't gotten any stronger since the mid-2000s trials stalled out. Neither review reports new positive obesity trial data for AOD-9604. If a major new randomized trial had shown a clean, reproducible weight-loss effect, that would be a big deal in the peptide world and would show up prominently in reviews like these. It hasn't happened.

How does AOD-9604's trial record compare to other GH-based peptides?

AOD-9604 stalled at Phase IIb for obesity. Tesamorelin got full FDA approval in 2010, backed by randomized trials showing measurable visceral adipose tissue reduction in a specific population (HIV-associated lipodystrophy), which is a much narrower and better-defined indication than general obesity. That's a meaningfully different evidence tier, and it's worth being blunt about it.

A 2003 paper titled "Gateways to Clinical Trials," published in Methods and Findings in Experimental and Clinical Pharmacology, surveys drugs including AOD-9604 as they moved through various stages of the clinical pipeline that year, giving a snapshot of where it sat among other investigational compounds ^[15]. A follow-up entry in the same journal series in 2003 covers a further set of compounds moving through trial gateways ^[16], and a 2005 installment continues tracking pipeline compounds including AOD-9604's ongoing development status ^[17]. Reading these three snapshots together, you can trace AOD-9604 moving through early and mid-stage trials over roughly three years without ever breaking through to a confirmatory Phase III program or an approval filing. If you're deciding between AOD-9604 and a peptide with a stronger evidence base, the AOD-9604 vs tesamorelin comparison is the more useful next read.

Why did AOD-9604's obesity trials stall instead of leading to approval?

Nobody has published a single clean explanation, and that's honest: the public record shows the trials, not the internal decision memos. What we can say is that the pattern, Phase IIb testing followed by no Phase III program and no approval filing, is consistent with a treatment effect too small or too inconsistent to justify the cost of a confirmatory trial. Running a Phase III obesity trial costs tens of millions of dollars and takes years. Companies don't walk away from that investment lightly if the Phase II data looked strong. The fact that Metabolic Pharmaceuticals didn't push AOD-9604 into Phase III for obesity, and that no other sponsor picked it up and did so since, is itself informative, even without a published "here's exactly why we stopped" statement. The 2006 obesity drugs review captures AOD-9604 as one candidate among many in a competitive field of obesity pharmaceuticals being developed around that time, most of which also failed to reach market ^[2]. Obesity drug development in general has a brutal failure rate. AOD-9604's stall isn't unique in that sense, but it does mean the compound never got the kind of large, definitive human trial that would let anyone say with confidence "this produces X pounds of fat loss over Y weeks compared to placebo." That sentence, the one everyone researching AOD-9604 wants answered, doesn't have solid trial data behind it.

What should someone researching AOD-9604 actually take away from the trial record?

Take away this: AOD-9604 has a real, defensible biochemical rationale (isolating the metabolic fragment of GH), it went through actual human trials rather than being pure theory, and it still failed to produce a weight-loss effect that regulators considered strong enough for approval. All three of those things are true at once, and none of them cancel the others out. If you're looking for a peptide with strong, reproducible human efficacy data for a metabolic indication, tesamorelin has that, at least for its specific approved population. AOD-9604 doesn't, and anyone selling it to you with confident claims about guaranteed fat loss is going beyond what the trial record supports. What AOD-9604 does have going for it: it's not flagged by the standard WADA hGH test ^[4], the safety signal from its trials wasn't the problem (efficacy was), and it remains an active area of research interest as reflected in the 2026 peptide reviews ^[13][14]. That's a genuinely different profile from a compound that failed on safety grounds. It's a compound that failed to prove it works well enough, which is a lower bar to clear in theory but one it still didn't clear. If you're going to use it anyway, informed by this record rather than despite it, do it through a provider-reviewed pathway rather than an anonymous research chemical vendor with no quality oversight. AOD-9604 Co works with a provider-reviewed process and names its fulfilling pharmacy partner rather than compounding or manufacturing anything itself, which at minimum gets you a sourcing chain with some accountability attached, even though it doesn't change what the underlying trial data says.

Where does AOD-9604 fit if you're comparing peptides for fat loss?

Honestly, low on the list if reproducible human efficacy is your main criterion. AOD-9604's obesity trials are the best human data we have on it, and they didn't separate from placebo convincingly ^[1][2]. That's a specific, checkable claim, and it's the one that should anchor your expectations rather than forum testimonials or vendor marketing copy. If you're set on trying it anyway, for whatever reason, the practical questions become about how and when to use it correctly rather than whether it works. The when to take AOD-9604 peptide guide and the how to reconstitute AOD-9604 guide cover the practical side. If you're shopping for it, AOD-9604 peptide for sale and best place to buy AOD-9604 cover sourcing considerations, including why provider-reviewed pathways matter more for a compound with this kind of regulatory gap than for an FDA-approved drug where quality control is baked into the approval process itself.

Frequently asked questions

Did AOD-9604 pass its human obesity trials?

It reached Phase IIb human testing for obesity in the mid-2000s but the weight-loss effect did not separate convincingly from placebo. It never advanced to Phase III and was never approved by the FDA or any other major regulator for obesity or any other indication.

Is there a published clinical trial showing AOD-9604 causes fat loss in humans?

There's no large, confirmatory randomized trial showing a clean, reproducible fat-loss effect. Reviews from 2004 and 2006 place AOD-9604 in the investigational obesity drug pipeline, but the compound stalled at Phase IIb without a positive Phase III result ever being published ^[1][2].

Why isn't AOD-9604 FDA approved if it went through trials?

Going through Phase IIb trials doesn't guarantee approval. AOD-9604's weight-loss results in humans weren't strong or consistent enough to justify a Phase III program, and no approval application has ever been filed. It doesn't appear in the FDA's Drugs@FDA database of approved products.

Is AOD-9604 banned by WADA or detectable in a doping test?

It's not currently on WADA's prohibited list, and a 2013 study found it doesn't trigger the standard hGH isoform immunoassay used in anti-doping testing ^[4]. Newer mass spectrometry methods for small peptides are expanding what labs can detect, so status can change; always check current rules.

Can a compounding pharmacy legally make AOD-9604 in the US?

AOD-9604 doesn't appear on the FDA's 503A or 503B bulk drug substances lists, the lists that govern what compounders can legally use. That means it sits outside the framework for legitimate pharmacy compounding under 21 U.S.C. 353a, and it's typically sold as a research chemical instead.

How does AOD-9604 compare to tesamorelin for evidence quality?

Tesamorelin has FDA approval (2010) backed by randomized trials showing measurable visceral fat reduction in HIV-associated lipodystrophy. AOD-9604 has no approval and its obesity trials didn't separate from placebo convincingly. Tesamorelin's evidence is narrower in population but far stronger in quality.

What is the fragment rationale behind AOD-9604 supposed to do?

AOD-9604 is built from amino acids 176-191 of human growth hormone, the region researchers believed carried GH's fat-metabolizing activity without its growth-promoting effects. The idea was fat-cell signaling without the joint, tissue, and insulin risks tied to full GH ^[1].

Are there safety concerns from AOD-9604's human trials?

The public record indicates AOD-9604's trials stalled on efficacy, not safety. That said, there's no large published safety database comparable to an approved drug's label, so long-term safety data outside the original trial population is limited.

Do any 2026 studies support AOD-9604 for fat loss?

Two 2026 reviews, one in JAAOS Global Research & Reviews and one in Sports Medicine, discuss AOD-9604 within broader peptide therapeutics research, but neither reports new positive obesity trial data. The efficacy picture hasn't materially changed since the mid-2000s trials stalled ^[13][14].

Is AOD-9604 the same as HGH?

No. AOD-9604 is a small fragment (amino acids 176-191) of the full human growth hormone molecule, roughly 1.8 kDa versus full HGH's much larger structure. It's designed to isolate one proposed metabolic activity rather than replicate whole GH.

Where can I find a provider-reviewed source for AOD-9604?

Given the regulatory gap (no FDA approval, absent from 503A/503B bulk lists), a provider-reviewed pathway with a named fulfilling pharmacy partner gives more accountability than an anonymous research chemical vendor, though it doesn't change what the underlying trial data shows.

Has anyone run a new AOD-9604 obesity trial since the original Phase IIb studies?

No large new confirmatory trial has been published. The original mid-2000s Phase IIb program remains the primary human efficacy data source, and subsequent literature (through 2026) discusses AOD-9604 in review and mechanism contexts rather than reporting new placebo-controlled weight-loss results.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604 as the metabolic fragment of GH under investigation, distinct from GH's growth-promoting activity
2. PubMed, Current Opinion in Investigational Drugs (2006): Places AOD-9604 within the obesity drug development pipeline of the mid-2000s alongside other candidates that failed to reach market
3. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product in this database
4. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence or trigger the WADA hGH isoform immunoassay used in anti-doping testing
5. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical approaches for detecting emerging therapeutics and non-approved peptide drugs in doping controls
6. PubMed, Expert Review of Proteomics (2014): Reviews detection strategies for peptidic drugs, drug candidates, and analogs in sports doping
7. PubMed, Journal of Separation Science (2016): Describes a mass spectrometry method for screening peptides under 2 kDa via direct urine injection, relevant to AOD-9604's molecular size range
8. eCFR, 21 CFR 216.23 (503A Bulks List): AOD-9604 does not appear on the federal 503A bulk drug substances list for compounding
9. eCFR, 21 CFR 216.24 (503B Bulks List): AOD-9604 does not appear on the federal 503B bulk drug substances list for outsourcing facility compounding
10. Cornell Law School, 21 U.S.C. 353a: Sets the legal conditions under which compounding pharmacies may use bulk drug substances for patient-specific preparations
11. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA nomination and review process a substance must undergo before compounders can legally use it
12. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): AOD-9604 does not currently appear on the FDA's list of substances nominated and evaluated for 503A compounding use
13. PubMed, JAAOS Global Research & Reviews (2026): Discusses therapeutic peptides in orthopaedics, including applications, challenges, and future research directions relevant to peptides like AOD-9604
14. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, including unapproved peptides
15. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Surveys AOD-9604 among compounds moving through clinical trial pipeline stages in 2003
16. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Tracks a further set of investigational compounds moving through clinical trial gateways in 2003
17. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): Continues tracking AOD-9604's development status among pipeline compounds through 2005